IDEAYA Biosciences(NASDAQ) IDYA

IDEAYA Biosciences, Inc. treats cancer by targeting specific genetic changes. These medicines help patients with rare and difficult tumors. The firm finds exact genetic causes to fight disease.

What Is IDEAYA Building?

• Darovasertib: Oral drug for uveal melanoma, a rare eye cancer; currently in late-stage clinical trials.
• IDE397: Small molecule targeting specific genetic deletions in solid tumors; currently in early clinical testing.
• IDE849: Antibody-drug conjugate that delivers medicine directly to cancer cells; targets small-cell lung cancer.
• IDE892: Oral therapy designed for patients with tumors missing the MTAP gene; evaluated as a combination therapy.
• IDE161: Treatment targeting PARG proteins to improve how other cancer medicines work in the body.

Strategic Steps and Alliances

• Partnered with Servier in Aug. 2025 to develop and sell darovasertib outside the United States.
• Teamed up with Roche in May 2026 to test a combined therapy for pancreatic cancer.
• Raised $323.4 million in net proceeds through a public stock offering in June 2026.
• Dosed the first patient with IDE034 in the first quarter of 2026, triggering a milestone payment.

How IDEAYA Stands Out

IDEAYA uses synthetic lethality to kill cancer cells without harming healthy ones. This method works by targeting gene pairs that only cause cell death when both are inactive.

The Numbers Behind the Research

• Cash, cash equivalents, and marketable securities totaled $1.24 billion as of June 30, 2026.
• Collaboration revenue was $15.4 million for the six-month period ended June 30, 2026.
• Net loss reached $211.0 million for the six-month period ended June 30, 2026, up from $149.7 million in the prior-year period.
• Research and development expenses rose 41% to $204.4 million for the six months ended June 30, 2026.
• The company reported an accumulated deficit of $947.5 million as of June 30, 2026.

Bottom Line

IDEAYA has moved from early research to late-stage clinical testing of precision oncology treatments. Its strategy involves using partnerships and a large cash reserve to develop multiple cancer therapies.